New publication : Mitochondrial morphodynamics alteration induced by influenza virus infection as a new antiviral strategy

Published on 19/02/2021

Together with the team of Etienne Morel, ENYO Pharma continues the antiviral exploration of its molecule targeting the NEET proteins, in the context of influenza virus. In this new article, we demonstrate that MITO-C exerts a membrane signature that strictly counteracts the signature applied by influenza virus infection on the mitochondria and on endoplasmic reticulum-mitochondria contact sites. Consequently, MITO-C potentiates Interferon expression and inhibits viral replication. Publication here

Read next in 'Latest news'

• Enrollment completed for our Phase 2 clinical trial in Alport syndrome
• The first patient dosed in the Phase 2 ALPESTRIA-1 clinical study of Vonafexor for Alport syndrome
• The Phase 2 ALPESTRIA-1 clinical study has started with Vonafexor on Alport syndrome
• Orphan Drug Designation (ODD) granted to Vonafexor for Alport syndrome by both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA)
• New publication: Hepatic and renal improvements with FXR agonist Vonafexor in individuals with suspected fibrotic NASH